Literature DB >> 10603618

The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease.

K J Smith1, W I McDonald.   

Abstract

The pathophysiology of multiple sclerosis is reviewed, with emphasis on the axonal conduction properties underlying the production of symptoms, and the course of the disease. The major cause of the negative symptoms during relapses (e.g. paralysis, blindness and numbness) is conduction block, caused largely by demyelination and inflammation, and possibly by defects in synaptic transmission and putative circulating blocking factors. Recovery from symptoms during remissions is due mainly to the restoration of axonal function, either by remyelination, the resolution of inflammation, or the restoration of conduction to axons which persist in the demyelinated state. Conduction in the latter axons shows a number of deficits, particularly with regard to the conduction of trains of impulses and these contribute to weakness and sensory problems. The mechanisms underlying the sensitivity of symptoms to changes in body temperature (Uhthoff's phenomenon) are discussed. The origin of 'positive' symptoms, such as tingling sensations, are described, including the generation of ectopic trains and bursts of impulses, ephaptic interactions between axons and/or neurons, the triggering of additional, spurious impulses by the transmission of normal impulses, the mechanosensitivity of axons underlying movement-induced sensations (e.g. Lhermitte's phenomenon) and pain. The clinical course of the disease is discussed, together with its relationship to the evolution of lesions as revealed by magnetic resonance imaging and spectroscopy. The earliest detectable event in the development of most new lesions is a breakdown of the blood-brain barrier in association with inflammation. Inflammation resolves after approximately one month, at which time there is an improvement in the symptoms. Demyelination occurs during the inflammatory phase of the lesion. An important mechanism determining persistent neurological deficit is axonal degeneration, although persistent conduction block arising from the failure of repair mechanisms probably also contributes.

Entities:  

Mesh:

Year:  1999        PMID: 10603618      PMCID: PMC1692682          DOI: 10.1098/rstb.1999.0510

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  234 in total

1.  Electrophysiological properties of spinal motoneurones of normal and dystrophic mice.

Authors:  P Huizar; M Kuno; Y Miyata
Journal:  J Physiol       Date:  1975-06       Impact factor: 5.182

2.  Conduction in segmentally demyelinated mammalian central axons.

Authors:  P A Felts; T A Baker; K J Smith
Journal:  J Neurosci       Date:  1997-10-01       Impact factor: 6.167

3.  The hot bath test in the diagnosis of multiple sclerosis.

Authors:  A S Malhotra; H Goren
Journal:  JAMA       Date:  1981-09-04       Impact factor: 56.272

4.  Conduction through demyelinated plaques in multiple sclerosis: computer simulations of facilitation by short internodes.

Authors:  S G Waxman; M H Brill
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-05       Impact factor: 10.154

5.  Changed distribution of sodium channels along demyelinated axons.

Authors:  J D England; F Gamboni; S R Levinson; T E Finger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Anti-synaptic antibody in allergic encephalomyelitis. I. Neurophysiological studies, in guinea pigs, on the exposed cerebral cortex and peripheral nerves, following immunological challenges with myelin and synaptosomes.

Authors:  C E Lumsden; L Howard; S R Aparicio
Journal:  Brain Res       Date:  1975-08-08       Impact factor: 3.252

7.  Multiple sclerosis: a serial study using MRI in relapsing patients.

Authors:  C Isaac; D K Li; M Genton; C Jardine; E Grochowski; M Palmer; L F Kastrukoff; J Oger; D W Paty
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

8.  Factors in the cerebrospinal fluid of multiple sclerosis patients interfering with voltage-dependent sodium channels.

Authors:  H Brinkmeier; K H Wollinsky; M J Seewald; P J Hülser; H H Mehrkens; H H Kornhuber; R Rüdel
Journal:  Neurosci Lett       Date:  1993-06-25       Impact factor: 3.046

9.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

10.  Physiological consequences of antiserum-mediated experimental demyelination in CNS.

Authors:  R Kaji; A Suzumura; A J Sumner
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

View more
  63 in total

Review 1.  Rehabilitation interventions in multiple sclerosis: an overview.

Authors:  Serafin Beer; Fary Khan; Jürg Kesselring
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

Review 2.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

Review 3.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 4.  Uhthoff's phenomena in MS--clinical features and pathophysiology.

Authors:  Teresa C Frohman; Scott L Davis; Shin Beh; Benjamin M Greenberg; Gina Remington; Elliot M Frohman
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

5.  Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis.

Authors:  Carmen Tur; Olivia Goodkin; Daniel R Altmann; Thomas M Jenkins; Katherine Miszkiel; Alessia Mirigliani; Camilla Fini; Claudia A M Gandini Wheeler-Kingshott; Alan J Thompson; Olga Ciccarelli; Ahmed T Toosy
Journal:  Brain       Date:  2016-02-17       Impact factor: 13.501

Review 6.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

Review 7.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

8.  Cuprizone-induced oligodendrocyte loss and demyelination impairs recording performance of chronically implanted neural interfaces.

Authors:  Steven M Wellman; Kelly Guzman; Kevin C Stieger; Lauren E Brink; Sadhana Sridhar; Mitchell T Dubaniewicz; Lehong Li; Franca Cambi; Takashi D Y Kozai
Journal:  Biomaterials       Date:  2020-02-06       Impact factor: 12.479

9.  Short-latency afferent inhibition predicts verbal memory performance in patients with multiple sclerosis.

Authors:  Laura Cucurachi; Paolo Immovilli; Franco Granella; Giovanni Pavesi; Luigi Cattaneo
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

10.  Contribution of relapses to disability in multiple sclerosis.

Authors:  Claire Hirst; Gillian Ingram; Owen Pearson; Trevor Pickersgill; Neil Scolding; Neil Robertson
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.